A study testing whether a GLP-1 medicine from Eccogene, semaglutide, can help with weight.
What this means for you
- Who can join
- Adults 18 to 75, have obesity, BMI 30+.
- What you take
- semaglutide, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.
- How long it lasts
- The study runs about 8 months.
- What you get
- The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.
What this study is for
Primary condition: Adult Obesity. Also studied in: Weight Management.
Full scientific study title: MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial.
Who can join
Adults 18 to 75, have obesity, BMI 30+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- Capable of providing written informed consent and complying with all trial procedures.
- Willing to comply with contraception requirements (as applicable to males and females of childbearing potential).
- Obese with BMI >=30 kg/m^2 and stable body weight within 6 months prior to screening.
- HbA1c <=6.5%.
- Estimated glomerular filtration rate (eGFR) >=60 mL/min/1.73 m^2 (per CKD-EPI 2021 formula).
Key exclusion criteria
- History or current diagnosis of type 1 or type 2 diabetes mellitus.
- Weight change >5% of total body weight within 6 months prior to screening or planned initiation of a weight loss program or use of weight-altering medication.
- Obesity induced by endocrine disorders such as Cushing's syndrome or monogenic or syndromic obesity such as Prader-Willi syndrome.
- Use of GLP-1 agonist treatment within the last 6 months prior to screening.
- History or current evidence of a pituitary disorder.
Where this study is enrolling
This trial has 15 sites across 10 states. Contact a site coordinator directly to start screening.
Alabama1 site
- Central Research Associates - Flourish - PPDSBirmingham, Alabama
California2 sites
- Anaheim Clinical Trials LLC - Anaheim - CenExel - PPDSAnaheim, California
- Collaborative Neuroscience Network - Los Alamitos- CenExel - PPDSLos Alamitos, California
Florida2 sites
- AES - DRS - Optimal Research Florida - MelbourneMelbourne, Florida
- ForCare Clinical Research - CenExel FCR - PPDSTampa, Florida
Georgia2 sites
- Atlanta Center for Medical Research - CenExel ACMR - PPDSAtlanta, Georgia
- iResearch Atlanta - CenExel - PPDSDecatur, Georgia
Minnesota1 site
- AES - DRS - Synexus Clinical Research US, Inc. - Richfield - MinneapolisRichfield, Minnesota
Nebraska1 site
- Velocity Clinical Research (3345 N 107th St) - Omaha - Nebraska - PPDSOmaha, Nebraska
North Carolina1 site
- Velocity Clinical Research - Durham - PPDSDurham, North Carolina
Ohio1 site
- Velocity Clinical Research - Cincinnati (Springdale) - Ohio - PPDSCincinnati, Ohio
Rhode Island1 site
- Velocity Clinical Research - Providence - PPDSEast Greenwich, Rhode Island
Texas3 sites
- Velocity Clinical Research - Dallas - PPDSDallas, Texas
- AES - DRS - Synexus Clinical Research US, Inc. - San AntonioSan Antonio, Texas
- Flourish Research - San Antonio - PPDSSan Antonio, Texas
Timeline
Started enrolling: 2026-03-13. Expected completion: 2026-11-20. Last updated on ClinicalTrials.gov: 2026-04-01.
Official source
We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
